Clinical trials
Myasthenia Gravis trials in Belgium
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
31 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 4 |
| 2021 | 6 |
| 2022 | 1 |
| 2024 | 9 |
| 2025 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 14 |
| Recruiting | 9 |
| Active, not recruiting | 5 |
| Enrolling by invitation | 1 |
| Terminated | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| argenx | 14 |
| Alexion Pharmaceuticals, Inc. | 2 |
| CuraVac | 2 |
| Grifols Therapeutics LLC | 2 |
| Momenta Pharmaceuticals, Inc. | 2 |
| Centre Hospitalier Universitaire de Liege | 1 |
| Janssen Research & Development, LLC | 1 |
| Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 1 |
| Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 1 |
| NMD Pharma A/S | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Myasthenia Gravis | 31 |
| Charcot-Marie-Tooth Disease | 1 |
| Huntington Disease | 1 |
| Lambert-Eaton Myasthenic Syndrome | 1 |
| Multiple Sclerosis | 1 |
| Muscular Dystrophy, Facioscapulohumeral | 1 |
| Myotonic Dystrophy | 1 |
| Neuromuscular Diseases | 1 |
| Obesity | 1 |
| Spastic Paraplegia, Hereditary | 1 |
Trials
Showing 26 to 31 of 31. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.